GlassScriptPhysician profile
Raulie H Lo
NPI 1396712220
$1,808.04
in general payments reported to CMS, 2019-2025
26 companies · $545 in 2025
The $545 reported for 2025 was more than what 94% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $31.67 · 2022: $198 · 2023: $244 · 2024: $789 · 2025: $545.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,578.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,578.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $409.08 | 2023-2025 | Qelbree, Qelbree |
| Glaxosmithkline, LLC. | $193.50 | 2022-2025 | Shingrix, Bexsero, Arexvy |
| Merck Sharp & Dohme LLC | $181.89 | 2024-2025 | Vaxelis, Vaxneuvance, Gardasil 9 |
| Sanofi Pasteur INC. | $127.66 | 2022-2025 | |
| Novo Nordisk INC | $124.99 | 2021-2024 | |
| Cranial Technologies, INC | $87.28 | 2024-2025 | Doc Band |
| Xeris Pharmaceuticals, INC. | $72.12 | 2024 | Gvoke Hypopen |
| Abbvie INC. | $68.90 | 2022-2025 | |
| Agios Pharmaceuticals, INC. | $68.56 | 2025 | Pyrukynd |
| Ars Pharmaceuticals Operations, INC. | $51.12 | 2025 | Neffy |
| Shield Therapeutics INC | $47.36 | 2024 | |
| Alk-Abello, INC | $46.82 | 2025 | Neffy |
| Corium, LLC | $40.81 | 2023-2024 | Azstarys |
| Janssen Pharmaceuticals, INC | $39.85 | 2025 | Spravato |
| Avion Pharmaceuticals | $38.72 | 2023 | Methylphenidate Hydrochloride |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $38.62 | 2025 | Dexcom G6 Transmitter |
| Dynavax Technologies Corporation | $22.92 | 2024 | Heplisav-B |
| Amarin Pharma, INC. | $20.78 | 2022 | |
| Astellas Pharma US INC | $17.41 | 2025 | Veozah |
| Pfizer INC. | $17.35 | 2021 | |
| Lilly USA, LLC | $17.21 | 2023 | Emgality, Jardiance, Baqsimi |
| Collegium Pharmaceutical, INC. | $16.86 | 2025 | Jornay Pm |
| Amgen INC. | $16.47 | 2022 | |
| Kaleo, INC. | $14.29 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.08 | 2025 | Zoryve |
| Si-Bone, INC. | $13.39 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raulie Lo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.